 WALTHAM, Mass., Aug. 12, 2021 GLOBE NEWSWIRE -- EyeGate Pharmaceuticals, Inc. NASDAQ: EYEG, EyeGate or the Company, a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent corporate and operational activities. 